Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX008 for CDKL5 Deficiency Disorder (Phase 3, randomized, placebo-controlled, with open-label extension)
jRCT2041230015Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Apr 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of fenfluramine in CDKL5 deficiency disorder (CDD) (3 arms), sponsored by UCB. Started Apr 2023; status: active, not recruiting.
02
Drugs
fenfluramine
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on jRCT2041230015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230015.